Corcept Therapeutics (NASDAQ:CORT) Upgraded to Buy at BidaskClub

BidaskClub upgraded shares of Corcept Therapeutics (NASDAQ:CORT) from a hold rating to a buy rating in a research note issued to investors on Tuesday, BidAskClub reports.

Several other equities analysts have also recently weighed in on the stock. ValuEngine cut shares of Corcept Therapeutics from a sell rating to a strong sell rating in a research note on Tuesday, February 4th. Zacks Investment Research cut shares of Corcept Therapeutics from a hold rating to a sell rating and set a $14.00 target price for the company. in a research note on Tuesday, February 4th. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the company’s stock. Corcept Therapeutics presently has an average rating of Hold and a consensus price target of $16.50.

CORT opened at $13.34 on Tuesday. The stock has a market capitalization of $1.51 billion, a price-to-earnings ratio of 18.53 and a beta of 1.25. The company has a fifty day moving average of $12.77 and a 200 day moving average of $13.33. Corcept Therapeutics has a fifty-two week low of $9.55 and a fifty-two week high of $17.48.

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Ingalls & Snyder LLC grew its stake in shares of Corcept Therapeutics by 2.2% in the 3rd quarter. Ingalls & Snyder LLC now owns 8,712,176 shares of the biotechnology company’s stock worth $123,147,000 after buying an additional 190,377 shares in the last quarter. Renaissance Technologies LLC grew its stake in shares of Corcept Therapeutics by 19.1% in the 4th quarter. Renaissance Technologies LLC now owns 7,768,214 shares of the biotechnology company’s stock worth $93,995,000 after buying an additional 1,244,005 shares in the last quarter. State Street Corp grew its stake in shares of Corcept Therapeutics by 3.8% in the 4th quarter. State Street Corp now owns 3,027,521 shares of the biotechnology company’s stock worth $36,633,000 after buying an additional 112,000 shares in the last quarter. LSV Asset Management grew its stake in shares of Corcept Therapeutics by 57.7% in the 4th quarter. LSV Asset Management now owns 1,718,424 shares of the biotechnology company’s stock worth $20,792,000 after buying an additional 629,038 shares in the last quarter. Finally, Parallel Advisors LLC grew its stake in shares of Corcept Therapeutics by 10.0% in the 4th quarter. Parallel Advisors LLC now owns 1,405,895 shares of the biotechnology company’s stock worth $17,011,000 after buying an additional 128,044 shares in the last quarter. 72.49% of the stock is owned by institutional investors.

Corcept Therapeutics Company Profile

Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery.

Featured Article: What is the Current Ratio?

Receive News & Ratings for Corcept Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corcept Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.